1. Home
  2. Vol 10, No 1 (2025)
  3. Soemarwoto

SERUM METALLOPRETEINASE 3 (MMP-3) LEVELS IN LUNG CANCER AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS

Retno Ariza Soemarwoto(1), Syazili Mustofa(2), Sukarti San Suwarno(3), Faisal Yunus(4), Raden Dicky Wirawan Listiandoko(5), Fransisca TY Sinaga(6), Isura Febrihartati(7*)
(1) University of Lampung
(2) Department of Pulmonolgy and Respiratory Medicine, Faculty of Medicine, University of Lampung, Indonesia
(3) Department of Pulmonolgy and Respiratory Medicine, Faculty of Medicine, University of Lampung, Indonesia
(4) Department of Pulmonolgy and Respiratory Medicine, Faculty of Medicine, University of Lampung, Indonesia.
(5) Faculty of Medicine, Universitas of Aisyah Pringsewu, Indonesia
(6) Department of Pulmonolgy and Respiratory Medicine, Faculty of Medicine, University of Lampung, Indonesia
(7) Department of Pulmonolgy and Respiratory Medicine, Faculty of Medicine, University of Lampung, Indonesia
(*) Corresponding Author
DOI : 10.30604/jika.v10i1.3077

Abstract

Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer are among the diseases with high mortality rates and a similar genetic disposition. COPD is known to be a significant risk factor for lung cancer. Matrix metalloproteinase-3 (MMP-3) is a protein that plays a role in the growth stage of cancer that has the potential to develop COPD into lung cancer. This descriptive observational study aimed to compare plasma MMP-3 levels among four groups: healthy individuals, lung cancer patients, COPD patients, and patients with both lung cancer and COPD. The findings revealed that plasma MMP-3 levels were lowest in the healthy group and higher in the other groups. The increase in plasma MMP-3 levels among pathological subjects suggests a potential association between serum MMP-3 levels and the development of lung cancer in COPD patients. However, further research is needed to clarify this relationship.

Keywords


Chronic Obstructive Pulmonary Disease, Lung Cancer, Matrix Metalloproteinase-3

References


Ahn, S. V., Lee, E., Park, B., Jung, J. H., Park, J. E., Sheen, S. S., Park, K. J., Hwang, S. C., Park, J. B., Park, H.-S., & Park, J. H. (2020). Cancer development in patients with COPD: a retrospective analysis of the National Health Insurance Service-National Sample Cohort in Korea. BMC Pulmonary Medicine, 20(1), 170. https://doi.org/10.1186/s12890-020-01194-8

Brzóska, K., Bart?omiejczyk, T., Sochanowicz, B., Cymerman, M., Grudny, J., Ko?akowski, J., Kapka-Skrzypczak, L., Kruszewski, M., Sliwi?ski, P., & Roszkowski-?li?, K. (2014). Matrix metalloproteinase 3 polymorphisms as a potential marker of enhanced susceptibility to lung cancer in chronic obstructive pulmonary disease subjects. Annals of Agricultural and Environmental Medicine : AAEM, 21(3), 546–551. https://doi.org/10.5604/12321966.1120599

Christopoulou, M.-E., Papakonstantinou, E., & Stolz, D. (2023). Matrix Metalloproteinases in Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences, 24(4). https://doi.org/10.3390/ijms24043786

Dimic-Janjic, S., Hoda, M. A., Milenkovic, B., Kotur-Stevuljevic, J., Stjepanovic, M., Gompelmann, D., Jankovic, J., Miljkovic, M., Milin-Lazovic, J., Djurdjevic, N., Maric, D., Milivojevic, I., & Popevic, S. (2023). The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity. European Journal of Medical Research, 28(1), 127. https://doi.org/10.1186/s40001-023-01094-7

Friedlaender, A., Liu, S. V, Passaro, A., Metro, G., Banna, G., & Addeo, A. (2020). The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. Clinical Lung Cancer, 21(6), e539–e543. https://doi.org/10.1016/j.cllc.2020.04.006

Husebø, G. R., Nielsen, R., Hardie, J., Bakke, P. S., Lerner, L., D’Alessandro-Gabazza, C., Gyuris, J., Gabazza, E., Aukrust, P., & Eagan, T. (2019). Risk factors for lung cancer in COPD - results from the Bergen COPD cohort study. Respiratory Medicine, 152, 81–88. https://doi.org/10.1016/j.rmed.2019.04.019

Lam, D. C.-L., Liam, C.-K., Andarini, S., Park, S., Tan, D. S. W., Singh, N., Jang, S. H., Vardhanabhuti, V., Ramos, A. B., Nakayama, T., Nhung, N. V., Ashizawa, K., Chang, Y.-C., Tscheikuna, J., Van, C. C., Chan, W. Y., Lai, Y.-H., & Yang, P.-C. (2023). Lung Cancer Screening in Asia: An Expert Consensus Report. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 18(10), 1303–1322. https://doi.org/10.1016/j.jtho.2023.06.014

Lilenbaum, R. C., Cashy, J., Hensing, T. A., Young, S., & Cella, D. (2008). Prevalence of poor performance status in lung cancer patients: implications for research. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 3(2), 125–129. https://doi.org/10.1097/JTO.0b013e3181622c17

Lobb, R. J., Visan, K. S., Wu, L.-Y., Norris, E. L., Hastie, M. L., Everitt, S., Yang, I. A., Bowman, R. V, Siva, S., Larsen, J. E., Gorman, J. J., MacManus, M., Leimgruber, A., Fong, K. M., & Möller, A. (2023). An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer. Communications Biology, 6(1), 68. https://doi.org/10.1038/s42003-022-04350-4

Lu, W., Eapen, M. S., Hardikar, A., Chia, C., Robertson, I., Singhera, G. K., Hackett, T. L., & Sohal, S. S. (2023). Epithelial-mesenchymal transition (EMT) changes in non-small cell lung cancer patients with early COPD. ERJ Open Research, 9 9(6 6), 581–2023. https://doi.org/10.1183/23120541.00581-2023

Mahor, D., Kumari, V., Vashisht, K., Galgalekar, R., Samarth, R. M., Mishra, P. K., Banerjee, N., Dixit, R., Saluja, R., De, S., & Pandey, K. C. (2020). Elevated serum matrix metalloprotease (MMP-2) as a candidate biomarker for stable COPD. BMC Pulmonary Medicine, 20(1), 302. https://doi.org/10.1186/s12890-020-01323-3

Mulyawan, E., & Setiawan, J. A. (2024). The correlation between smoking cumulative dose based on Brinkman Index with peak expiratory flow rate. Journal of General and Family Medicine, 25(4), 193–197. https://doi.org/10.1002/jgf2.694

Nader, C. P., Cidem, A., Verrills, N. M., & Ammit, A. J. (2019). Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer. Respiratory Research, 20(1), 222. https://doi.org/10.1186/s12931-019-1192-x

Niayesh-Mehr, R., Kalantar, M., Bontempi, G., Montaldo, C., Ebrahimi, S., Allameh, A., Babaei, G., Seif, F., & Strippoli, R. (2024). The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19. Cell Communication and Signaling, 22(1), 542. https://doi.org/10.1186/s12964-024-01925-y

Parris, B. A., O’Farrell, H. E., Fong, K. M., & Yang, I. A. (2019). Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. Journal of Thoracic Disease, 11(Suppl 17), S2155–S2172. https://doi.org/10.21037/jtd.2019.10.54

Suryadinata, R., Wirjatmadi, B., Andriani, M., & Sri Sumarmi, M. (2022). The Expression Change of Mmp-8 and Collagen Type-2 Intracell in Lung Tissue Due to Electronic Smoke Exposure. Jurnal Kesehatan Masyarakat, 18, 31–40. https://doi.org/10.15294/kemas.v17i2.26557

Tsay, J.-C. J., Hu, Y., Goldberg, J. D., Wang, B., Vijayalekshmy, S., Yie, T.-A., Bantis, K., Sterman, D. H., & Rom, W. N. (2020). Value of metalloproteinases in predicting COPD in heavy urban smokers. Respiratory Research, 21(1), 228. https://doi.org/10.1186/s12931-020-01496-9

Wei, C. (2023). The multifaceted roles of matrix metalloproteinases in lung cancer. Frontiers in Oncology, 13, 1195426. https://doi.org/10.3389/fonc.2023.1195426

Woode, D., Shiomi, T., & D’Armiento, J. (2015). Collagenolytic matrix metalloproteinases in chronic obstructive lung disease and cancer. Cancers, 7(1), 329–341. https://doi.org/10.3390/cancers7010329


Article Statistic

Abstract view : 278 times
PDF (Bahasa Indonesia) views : 211 times

Dimensions Metrics

How To Cite This :

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.